BR0210875A - Antìgenos de streptococcus do grupo b e fragmentos de dna correspondentes - Google Patents

Antìgenos de streptococcus do grupo b e fragmentos de dna correspondentes

Info

Publication number
BR0210875A
BR0210875A BR0210875-5A BR0210875A BR0210875A BR 0210875 A BR0210875 A BR 0210875A BR 0210875 A BR0210875 A BR 0210875A BR 0210875 A BR0210875 A BR 0210875A
Authority
BR
Brazil
Prior art keywords
group
dna fragments
corresponding dna
antigens
streptococcus
Prior art date
Application number
BR0210875-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Denis Martin
Stephane Rioux
Bernard R Brodeur
Josee Hamel
Martine Boyer
Original Assignee
Shire Biochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Biochem Inc filed Critical Shire Biochem Inc
Publication of BR0210875A publication Critical patent/BR0210875A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR0210875-5A 2001-07-06 2002-07-05 Antìgenos de streptococcus do grupo b e fragmentos de dna correspondentes BR0210875A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30310101P 2001-07-06 2001-07-06
PCT/CA2002/001019 WO2003004650A2 (en) 2001-07-06 2002-07-05 Group b streptococcus antigens and corresponding dna fragments

Publications (1)

Publication Number Publication Date
BR0210875A true BR0210875A (pt) 2004-06-22

Family

ID=23170538

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210875-5A BR0210875A (pt) 2001-07-06 2002-07-05 Antìgenos de streptococcus do grupo b e fragmentos de dna correspondentes

Country Status (10)

Country Link
US (2) US7393536B2 (enExample)
EP (1) EP1407023B1 (enExample)
JP (2) JP4374245B2 (enExample)
AT (1) ATE452191T1 (enExample)
AU (1) AU2002317107B2 (enExample)
BR (1) BR0210875A (enExample)
CA (1) CA2453062C (enExample)
DE (1) DE60234772D1 (enExample)
ES (1) ES2337773T3 (enExample)
WO (1) WO2003004650A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939087B2 (en) * 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
EP1343895B1 (en) * 2000-12-21 2008-06-18 ID Biomedical Corporation Streptococcus pyogenes antigens and corresponding dna fragments
JP2005514052A (ja) * 2001-12-21 2005-05-19 チルドレンズ ホスピタル アンド レジオナル メディカル センター Ｂ群連鎖球菌の新規の細胞表面プロテアーゼの使用
WO2012138470A2 (en) 2011-04-04 2012-10-11 Intelligent Medical Devices, Inc. Optimized oligonucleotides and methods of using same for the detection, isolation, amplification, quantitation, monitoring, screening, and sequencing of group b streptococcus
KR101675382B1 (ko) 2015-04-07 2016-11-14 (주) 씨에스코리아 황토보드 제조방법 및 그에 의해 제조되는 황토보드

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0618813B1 (en) 1992-09-16 2002-01-09 The University Of Tennessee Research Corporation Antigen of hybrid m protein and carrier for group a streptococcal vaccine
DE69836744T2 (de) 1997-09-12 2007-10-04 University Of Tennessee Research Foundation, Knoxville Gruppe a streptokokken-impfstoff
PL205041B1 (pl) 1998-12-23 2010-03-31 Id Biomedical Corp Izolowany polinukleotyd, wektor zawierający izolowany polinukleotyd, komórka gospodarza transfekowana lub transformowana za pomocą tego wektora, sposób wytwarzania polipeptydu kodowanego przez izolowany polinukleotyd, izolowany polipeptyd, chimeryczny polipeptyd, kompozycja do szczepionek zawierająca polipeptyd oraz jej zastosowanie w leczeniu lub zapobieganiu zakażeniu osobnika paciorkowcem
GB9921125D0 (en) 1999-09-07 1999-11-10 Microbial Technics Limited Proteins
US7939087B2 (en) * 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
FR2824074A1 (fr) 2001-04-26 2002-10-31 Pasteur Institut Sequence du genome streptococcus agalactiae, application au developpement de vaccins, d'outils de diagnostic, et a l'identification de cibles therapeutiques
US7262024B2 (en) 2001-12-20 2007-08-28 Id Biomedical Corporation Streptococcus antigens

Also Published As

Publication number Publication date
CA2453062A1 (en) 2003-01-16
US7740870B2 (en) 2010-06-22
JP5194199B2 (ja) 2013-05-08
CA2453062C (en) 2013-04-02
US20040242844A1 (en) 2004-12-02
WO2003004650A2 (en) 2003-01-16
JP2009240316A (ja) 2009-10-22
JP2005501534A (ja) 2005-01-20
DE60234772D1 (de) 2010-01-28
JP4374245B2 (ja) 2009-12-02
AU2002317107B2 (en) 2008-06-12
EP1407023B1 (en) 2009-12-16
US7393536B2 (en) 2008-07-01
ES2337773T3 (es) 2010-04-29
ATE452191T1 (de) 2010-01-15
EP1407023A2 (en) 2004-04-14
US20090042794A1 (en) 2009-02-12
WO2003004650A3 (en) 2003-05-30

Similar Documents

Publication Publication Date Title
WO2001058485A3 (en) Prophylactic and therapeutic antibodies against vaccina virus antigens
WO2003054007A3 (en) Streptococcus antigens
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
BR0213540A (pt) Compostos, método para o tratamento de enfermidades ou distúrbios em um paciente e composição farmacêutica que compreende os mesmos
ATE470676T1 (de) Anti-vegf-2 antikörper
BR0104830A (pt) Tratamento de combinação para a demência ou déficits cognitivos associados com a doença de alzheimer e com a doença de parkinson
DE602004024542D1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
BR0208142A (pt) Combinações compreendendo um agente antidiarréico e epotilona ou derivado de epotilona
LU91734I2 (fr) Menveo - oligosaccharide méningococcique du group Y conjugué à la protéine CRM197 de Corynebacteriumdiphteriae.
ATE500843T1 (de) Streptococcus pneumoniae proteine und impfstoffe
BRPI0408085A (pt) composição e método para o tratamento e prevenção de infecções entéricas bacterianas
WO2006065553A3 (en) Glycoconjugate vaccines containing peptidoglycan
BR0207487A (pt) Método de tratamento de tumores em mamìferos e uso de compostos de epotilona
WO2003007803A3 (en) Methods for diagnosing and treating alzheimer's disease and parkinson's disease
WO2002040702A3 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
PT932613E (pt) Expressao de bloqueio de factoes de virulencia em s. aureus
MA27059A1 (fr) Azithromycine en dose unique
WO2000058475A3 (en) Streptococcus pneumoniae antigens
WO2002039122A3 (en) Methods for the identification and the treatment of cardiovascular disease
EA200400197A1 (ru) Способы получения поливалентных бактериофагов для лечения бактериальных инфекций
BR0109164A (pt) Anticorpos monoclonais para o receptor humano para ldl, produção e uso dos mesmos
EA200100700A1 (ru) Гены и белки и их применение
WO2001040473A3 (en) Pseudomonas aeruginosa antigens
EP0955366A4 (en) ANTIGENIC PROTEIN FROM MALASSEZIA
UA107177C2 (uk) Імуногенна композиція цвс2 та спосіб приготування такої композиції

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: SHIRE BIOCHEM INC. (CA)

Free format text: ALTERADA A SEDE DO TITULAR CONFORME REQUERIDA ATRAVES DA PETICAO NO 020050112623/RJ DE 11/10/2005.

B25A Requested transfer of rights approved

Owner name: ID BIOMEDICAL CORPORATION (CA)

Free format text: TRANSFERIDO DE: SHIRE BIOCHEM INC.

B25G Requested change of headquarter approved

Owner name: ID BIOMEDICAL CORPORATION (CA)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070097786/RJ DE 17/07/2007.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: ID BIOMEDICAL CORPORATION OF QUEBEC (CA)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time